文献速递主动脉疾病

应用抗菌移植物重建原发性和继发性主动脉感染

Reconstruction of primary and secondary aortic infections with an antimicrobial graft.
PubMed 文献 · J Vasc Surg · 2022-12-23

本研究评估了使用结合银和三氯生的抗菌移植物Intergard Synergy对感染性自体主动脉瘤或血管(内)移植物感染进行原位重建后的生存率和免于再感染率。2014年2月至2020年4月共植入86个抗菌移植物,30天死亡率为14.0%,院内死亡率为22.1%,1年和2年生存率分别为74.0%和69.8%,免于再感染率分别为97.2%和95.0%。

要点

  • 抗菌移植物原位重建感染性自体主动脉瘤或血管(内)移植物感染的早期死亡率与股静脉和动脉同种异体移植物研究相当。
  • 感染性自体主动脉瘤生存率显著优于血管(内)移植物感染(P = .01),主动脉肠瘘生存更差(P = .001)。
  • 血管(内)移植物感染院内死亡率最高(34.6%),其中近50%为主动脉肠瘘。

核心结论

  • 使用抗菌移植物对感染性自体主动脉瘤或血管(内)移植物感染进行原位重建,显示出令人鼓舞的早期死亡率和中期再感染率。
  • 早期死亡率与股静脉(9%-16%)和动脉同种异体移植物(8%-28%)研究中的比率相当。

研究设计与样本

  • 2014年2月至2020年4月,共植入86个抗菌移植物用于主动脉感染。
  • 感染性自体主动脉瘤/血管(内)移植物感染和再感染的诊断基于主动脉移植物感染协作组标准。
  • 生存分析采用Kaplan-Meier法和log-rank P值。

主要发现

  • 抗菌移植物植入于32例感染性自体主动脉瘤、28例血管移植物感染和26例血管内移植物感染。
  • 中位年龄69.0岁(四分位距:62.0;74.0),合并冠心病21例(24.4%)、慢性肾病11例(12.8%)、癌症21例(24.4%)、免疫抑制27例(31.4%)。
  • 影像学显示浸润14例(16.3%)、积气10例(11.6%)、破裂16例(18.6%),包括22例主动脉肠瘘。
  • 症状包括发热37例(43.0%)、休克11例(12.8%)、疼痛47例(54.7%)。
  • 30天死亡率和院内死亡率分别为14.0%和22.1%(分别为12例和19例;感染性自体主动脉瘤3例[9.4%]、血管移植物感染7例[25.0%]、血管内移植物感染9例[34.6%])。

关键数值与推荐

  • 1年和2年生存率分别为74.0%(95%CI:63.3-82.1)和69.8%(95%CI:58.5-78.5)。
  • 感染性自体主动脉瘤生存率显著优于血管(内)移植物感染(P = .01),主动脉肠瘘生存更差(P = .001)。
  • 免于再感染率分别为97.2%(95%CI:89.2-99.3)和95.0%(95%CI:84.8-98.4),再感染6例(7.0%),需2次放射学/6次手术引流和2例移植物移除。
  • 一期通畅率分别为88.0%(95%CI:78.1-93.6)和79.9%(95%CI:67.3-88.1),感染性自体主动脉瘤与血管(内)移植物感染之间无显著差异(P = .16)。

临床怎么用

  • 对于感染性自体主动脉瘤或血管(内)移植物感染,使用抗菌移植物进行原位重建是一种可选方法。
  • 术后并发症发生70例(81.4%),其中44例(51.2%)返回手术室。
  • 修复方式包括中线剖腹术75例(87.2%),腹腔干阻断19例(22.1%),肾上阻断26例(30.2%),以及腹腔干(3例)、肠系膜(5例)、肾(13例)或腹下(4例)动脉重建和大网膜覆盖41例(48.8%)。
  • 主动脉肠瘘的胃肠道修复采用直接缝合14例(16.3%)或切除吻合8例(9.3%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In situ reconstruction (ISR) with autologous veins is the preferred method in infectious native aortic aneurysms (INAAs) or vascular (endo)graft infection (VGEI). However, access to biological substitutes can prove difficult and lacks versatility. This study evaluates survival and freedom from reinfection after ISR of INAA/VGEI using the antimicrobial Intergard Synergy graft combining silver and triclosan. METHODS: From February 2014 to April 2020, 86 antimicrobial grafts were implanted for aortic infection. The diagnosis of INAA/VGEI and reinfection was established based on the Management of Aortic Graft Infection Collaboration criteria. Survival was analyzed using the Kaplan-Meier method and log-rank P values. RESULTS: The antimicrobial graft was implanted in 32 cases of INAA, 28 of VGI, and 26 of VEI. The median age was 69.0 (interquartile range: 62.0; 74.0), with a history of coronary artery disease (n = 21; 24.4%), chronic kidney disease (n = 11; 12.8%), cancer (n = 21; 24.4%), and immunosuppression (n = 27; 31.4%). Imaging showed infiltration (n = 14; 16.3%), air (n = 10; 11.6%), and rupture (n = 16; 18.6% including 22 aortoenteric fistulae [AEnF]). Symptoms included fever (n = 37; 43.0%), shock (n = 11; 12.8%), and pain (n = 47; 54.7%). Repair was undertaken through a midline laparotomy in 75 cases (87.2%) and coeliac cross-clamping in 19 (22.1%), suprarenal in 26 (30.2%), plus celiac trunk (n = 3), mesenteric (n = 5), renal (n = 13), or hypogastric (n = 4) artery reconstruction, and omental flap coverage (n = 41; 48.8%). For AEnF, the gastrointestinal tract was repaired using direct suture (n = 14; 16.3%) or resection anastomosis (n = 8; 9.3%). Causative organisms were identified in 74 patients (86.0%), with polymicrobial infection in 32 (37.2%) and fungal coinfection in 7 (8.1%). Thirty-day and in-hospital mortality were 14.0% and 22.1% (n = 12 and 19, respectively, 3 INAA [9.4%], 7 VGI [25.0%], and 9 VEI [34.6%]). Seventy patients (81.4%) had a postoperative complication, 44 (51.2%) of whom returned to the operative room. The 1- and 2-year survival rates were 74.0% (95% confidence interval [CI]: 63.3-82.1) and 69.8% (95% CI: 58.5-78.5), respectively. Survival was significantly better for INAA vs VGEI (P = .01) and worse for AEnF (P = .001). Freedom from reinfection was 97.2% (95% CI: 89.2-99.3) and 95.0% (95% CI: 84.8-98.4) with six reinfections (7.0%) requiring two radiological/six surgical drainage and two graft removals. Primary patency was 88.0% (95% CI: 78.1-93.6) and 79.9% (95% CI: 67.3-88.1) with no significant difference between INAA and VGEI (P = .16). CONCLUSIONS: ISR of INAA or VGEI with the antimicrobial graft showed encouraging early mortality, comparable to the rates found in femoral vein (9%-16%) and arterial allograft (8%-28%) studies, as well as mid-term reinfection. The highest in-hospital mortality was noted for VEI including nearly 50% of AEnF.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Caradu C, Jolivet B, Puges M, et al. Reconstruction of primary and secondary aortic infections with an antimicrobial graft. J Vasc Surg. 2022. PMID: 36572322. doi:10.1016/j.jvs.2022.11.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。